Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia

MLA

Panpan Zhang, et al. “Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia.” Biomedicines; Volume 9; Issue 12; Pages: 1783, Nov. 2021. EBSCOhost, https://doi.org/10.3390/biomedicines9121783.

APA

Panpan Zhang, Wenxiu Lv, Shuhua Tan, Tuo Hu, Chenchen Lu, Ying Mei, Menglong Xu, Manman Chen, & Zhengli Bai. (2021). Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia. Biomedicines; Volume 9; Issue 12; Pages: 1783. https://doi.org/10.3390/biomedicines9121783

Chicago

Panpan Zhang, Wenxiu Lv, Shuhua Tan, Tuo Hu, Chenchen Lu, Ying Mei, Menglong Xu, Manman Chen, and Zhengli Bai. 2021. “Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia.” Biomedicines; Volume 9; Issue 12; Pages: 1783, November. doi:10.3390/biomedicines9121783.